Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2020-10-26 07:00:16
Oslo, Norway, 26 October 2020 - Targovax ASA (OSE: TRVX) will announce its third quarter 2020 results on Thursday 5 November 2020. An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 am CET. The results report and the presentation will be available at www.targovax.com (https://www.targovax.com/en/financial-reports/) in the Investors section from 07:00 am CET. Presentation As a consequence of the Corona situation, there will only be a virtual presentation of the results with a live webcast 5 November at 10.00 am CET. You can join the webcast here (https://channel.royalcast.com/webcast/hegnarmedia/20201105_3). It will be possible to ask questions during the presentation. For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media and IR enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.